Mortality and causes of death in HIV-positive patients receiving antiretroviral therapy at Tshepang Clinic in Doctor George Mukhari Hospital

Polskie Archiwum Medycyny Wewnetrznej

Volumn 118, Issue 10, 2008, Pages 548-554

  Mzileni, Mogiyana Olga ^a   Longo Mbenza, Benjamin ^a   Chephe, Tlou James ^a  

^a UNIVERSITY OF LIMPOPO   (South Africa)

Author keywords

Antiretroviral therapy; Causes of HIV infections; Mortality; Sub Aaharan Africa; Trends

Indexed keywords

ANTIRETROVIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROL GROUP; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PATIENT REFERRAL; PREVENTION AND CONTROL; PROSPECTIVE STUDY; SEX DIFFERENCE;

EID: 55849116722     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.486     Document Type: Article

References (31)

1. Palella FJ, Delaney KJ, Moorman AC, et al. Declining morbidity and mortality among patients with advanced Human Immunodeficiency Virus infection. N Eng J Med. 1998; 338: 853-860.
2. Centers for Disease Control and Prevention (CDC). Update: Trends in AIDS incidence, deaths, and prevalence - United States, 1996. MMWR Morb Mortal Wkly Rep. 1997; 46: 165-173.
3. Hogg RS, O'Shaughness MV, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet. 1997; 349: 1294 [Research Letter].
4. Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. Lancet. 1998; 352: 1725-1730.
5. Murphy El, Collier AC, Kalish LA, et al. Highly active antiretroviral therapy decreases mortality and morbidity in patients with advanced HIV disease. Ann Intern Med. 2001; 135: 17-26.
6. Ledergerber B, Egger M, Opravil M, at al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet. 1999; 353: 863-868.
7. Dayton JM, Nerson MH. Global dimensions of the AIDS epidemic: implications for prevention and care. Infect Dis Clin North Amer. 2000; 14: 4-9.
8. Dedicoat M, Reid A, Mbatha D, Click C. The Impact of HIV/AIDS related morbidity and mortality in a rural district hospital in South Africa. Int Conf AIDS. 2002: Jul 7-12: 14: Abstract No. Mope B3311.
9. Gilks CE, Floyd K, Otieno LS, et al. Some effects of the rising case load of adult HIV-related disease on a hospital in Nairobi. J Acquir Immune Defic Syndr Hum Retroviral. 1998; 18: 234-240.
10. Etard JF, Ndiaye I, Thierry-Mieg M, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS. 2006; 20: 1181-1189.
11. Palella FJ, Baker RK, Moorman AC, et al. HIV outpatient study investigators mortality in the highly active antiretroviral therapy era: Changing causes death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006; 43: 27-34.
12. Martinez E, Milinkovic A, Buira E, et al. Incidence and causes of death in HIV-infected persons receiving highly active antiretroviral therapy compared with estimates for the general population of similar ages and from the same geographical area. HIV Med. 2007; 8: 251-258.
13. Mocroft A, Brettle R, Kirk O, et al. Changes in the cause of death among HIV positive subjects across Europe: results from the Euro SIDA Study: AIDS. 2002; 16: 1663-1671.
14. Holmes CB, Losina E, Walensky RR et al. Review of human immuno-deficiency virus type 1-related opportunistic infections in sub-Saharan Africa. Clin Infect Dis. 2003; 36: 652-662.
15. Aaron I, Saadoum D, Calatroni I, et al. Tuberculosis in HIV-infected patients: a comprehensive review. Clin Microbiol Infect. 2004; 10: 388-398.
16. Attia A, Huet C, Anglaret X, et al. HIV-1 -related morbidity in adults, Abidjan, Cote d'Ivoire: a nidus for bacterial diseases. J Acquir Immune Defic Syndr. 2001; 28: 478-486.
17. The antiretroviral therapy in lower income countries (ART-LINC) collaboration and ART Cohort Collaboration (ART-CC) groups. Mortality of HIV-1 infected patients in the first year of antiretroviral therapy: companion between low-income and high-income countries. Lancet. 2006; 367: 817-824.
18. Egger M, May M, Chene G, et al. Prognosis of HIV-1 - infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002: 360: 119-129.
19. Hogg RS, Yip B, Kully C, et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ. 1999; 160: 659-665.
20. Sterne JA, Heman MA, Ledergerber B, et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study. Lancet. 2005; 366: 378-384.
21. Lewden C, Salmon D, Morlat P, et al. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int J Epidemiol. 2005; 34: 121-130.
22. Besson C, Goubar A, Gabarre J, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood. 2001; 98: 2339-2344.
23. Kirk O, Pedersen C, Cozzilepri A, et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood. 2001; 98: 3406-3412.
24. Krentz HB, Kliewer G, Gill MJ. Changing mortality rates and causes of death for HIV-infected individuals living in Southern Alberta, Canada from 1984 to 2003. HIV Med. 2005: 6: 99-106.
25. Sabin CA, Smith CJ, Youle M, et al. Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers. AIDS. 2006; 20: 67-71.
26. Jahn A, Floyd S, Crampin AC, et al. Population-level effect of HIV on adult mortality and early evidence of reverse after introduction of antiretroviral therapy in Malawi. Lancet. 2008; 371: 1603-1611.
27. Egger M, Boulle A. Population effect of scaling up ART in resource poor settings. Lancet. 2008; 371: 1558-1559.
28. Ojikutu BO, Zheng H, Walensky RP, et al. Predictors of mortality in patients initiating antiretroviral therapy in Durban, South Africa. S Afr Med J. 2008; 98: 204-208.
29. Mermin J, Were W, Ekwaru JP, et al. Mortality in HIV-infected Uganden adults receiving antiretroviral treatment and survival of their HIV-uninfected children: a prospective cohort study. Lancet. 2008; 371: 752-759.
30. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patience receiving HIV protease inhibitors. AIDS. 1998; 12: F51-F58.
31. Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS. 1999; 13: F63-F70.